Diabetes 🍬 Flashcards
Define type 2 diabetes
Insulin resistance and a relative insulin deficiency resulting in persisting hyperglycaemia
Risk factors for type 2 diabetes
Obesity
Physical inactivity
Family history
Ethnicity
Polycystic ovary syndrome
Diet
Statins / corticosteroids
Diagnosing type 2 diabetes
Persistent hyperglycaemia and / or blurred vision / unexplained weight loss / recurrent infections / dark pigmentation appearing in folds of skin / risk factors
Values of persistent hyperglycaemia
HbA1C 48 + mmol / L
Fasting plasma glucose 7+ mmol / L
Random plasma glucose 11 + mmol / L
Metformin action
Decreases gluconeogensis
Decreases intestinal absorption of glucose
Increases insulin sensitivity by increasing peripheral glucose uptake and utilisation (kidneys)
Metformin benefits
Weight neutral
Beneficial effect on ischaemic cardiovascular disease risk
Little risk of hypoglycaemia
Metformin cautions
NOT FOR EGFR OF LESS THAN 30 / creatinine 150+/ CKD stage 4
GI side effects (change to MR)
Can cause B12 deficiency (test if fatigue)
Stop if unwell / vomiting (renal failure)
Stop for 48 hours following radiological investigation involving IV contrast media (renal failure)
SGLT 2 inhibitor action (sodium-glucose co-transporter 2) (flozins)
Reversibly inhibits sodium-glucose co-transporter 2 in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose secretion (can cause UTIs)
Empagliflozin
Cardioprotective: use in Q risk 10+ / established CVD
SGLT 2 inhibitor benefits
Decreases HbA1C levels
Increased WEIGHT LOSS
decreased blood pressure
SGLT 2 inhibitor cautions
Genitourinary infections
Increased risk of diabetic ketoacidosis
Increased risk of acute kidney injury
Increased risk of amputation (Cana…flozin)
Increased risk of hypotension
Sulphonylureas (gliclazide) action
Augments insulin secretion. Only effective when some residual pancreatic beta-cell activity is present.
Sulphonylureas (gliclazide) benefits
Well established
Good if underweight
Rapid decreased blood glucose
Sulphonylureas (gliclazide) cautions
Risk of hypoglycaemia: higher risk for older people. Dangerous due to falls risk.
Weight gain
Dipeptidyl peptidase inhibitors (DPP - 4 inhibitors) action
Inhibits DPP-4 to increase insulin secretion and lower glucagon secretion.
Linagliptin
Mono / dual / triple therapy
DPP4i + Metformin or SU or Pio
DPP4i + Metformin + SU
DPP-4 inhibitor benefits
Lower risk of hypo
Generally weight neutral
HbA1C reduction